Bibliography
- Pariser AR, Robb M, Sherman RE. Expedited programs for drug development and approval. Expert Opin Orphan Drugs 2013;1(7):507-10
- Kux L. Final rule: orphan drug regulations. 21 CFR Part 316 [Docket No. FDA-2011-N-0583] RIN 0910-AG72 Food and Drug Administration. Federal Register 2013;78(113):35117-35
- Genetic and Rare Diseases Information Center (GARD) National Center for Advancing Translational Sciences, Office of Rare Disease Research. Available from: http://rarediseases.info.nih.gov
- GeneCards. Human Gene Database. Weizmann Institute of Science. 2013. Available from: http://www.genecards.org/
- MalaCards. Human Maladies and their annotations. Weizmann Institute of Science. 2013. Available from: http://www.malacards.org/
- Sudarsanam S, Johnson DE. Functional consequences of mTOR inhibition. Curr Opin Drug Discov Devel 2010;13(1):31-40
- Gough NR. Focus issue: TOR signaling, a tale of two complexes. Sci Signal 2012;5(217):eg4
- Kelsey I, Manning BD. mTORC1 status dictates tumor response to targeted therapeutics. Sci Signal 2013;6(294):pe31
- Azab SS. Targeting mTOR signaling pathways in breast cancer: more than the rapalogs. J Biochem Pharmacol Res 2013;1(2):75-83
- Kwan P, Tse MT. mTOR and its physiological impacts – part I: an overview. J Biochem Pharmacol Res 2013;1(2):124-37
- Shanmuganathan VA, Casely EM, Raj D, et al. The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol 2005;89(6):666-9
- Zhou P, Zhao MW, Li XX, et al. siRNA targeting mammalian target of rapamycin (mTOR) attenuates experimental proliferative vitreoretinopathy. Curr Eye Res 2007;32(11):973-84
- Kristof AS. mTOR signaling in lymphangioleiomyomatosis. Lymphat Res Biol 2010;8(1):33-42
- Knox C, Law V, Jewison T, et al. DrugBank 3.0: a comprehensive resource for ‘omics’ research on drugs. Nucleic Acids Res 2011;39:D1035-41. Available from: http://www.drugbank.ca/
- Margariti N, Fox SB, Bottini A, et al. Overcoming breast cancer drug resistance with mTOR inhibitors. Could it be a myth or a real possibility in the short term future? Breast Cancer Res Treat 2010;128(3):599-606
- Mark A, Hajdu M, Varadi Z, et al. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease – a combined tissue microarray, in vitro and in vivo study. BMC Cancer 2013;13:250-61
- Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010;35:14-26
- Davies DM, de Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 2011;17(12):4071-81
- McComack FX. Lymphangioleiomyomatosis: a clinical update. Chest 2008;133(2):507-16
- Young LR, Lee H-S, Inoue Y, et al. Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med 2013;1:445-52
- Vinci P, van der Graaf PH. Systems pharmacology for drug discovery and development: paradigm shift or flash in the pan. Clin Pharmacol Ther 2013;93(5):379-81